Your browser doesn't support javascript.
loading
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Gillessen, Sarah; Hüttmann, Andreas; Vucinic, Vladan; Müller, Horst; Plütschow, Annette; Viardot, Andreas; Topp, Max S; Kobe, Carsten; Böll, Boris; Eichenauer, Dennis A; Sasse, Stephanie; Haverkamp, Heinz; Schmitz, Christine; Borchmann, Sven; Bröckelmann, Paul J; Heger, Jan-Michel; Fuchs, Michael; Engert, Andreas; Borchmann, Peter; von Tresckow, Bastian.
Afiliación
  • Gillessen S; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Hüttmann A; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Vucinic V; Department of Hematology and Stem Cell Transplantation and Cancer Center Cologne Essen - Partner Site Essen, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Müller H; Department of Hematology and Oncology, University of Leipzig, Leipzig, Germany.
  • Plütschow A; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Viardot A; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Topp MS; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Kobe C; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Böll B; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
  • Eichenauer DA; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
  • Sasse S; German Hodgkin Study Group (GHSG), Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Haverkamp H; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Schmitz C; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Borchmann S; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Bröckelmann PJ; Cancer Center Cologne Essen - Partner Site Cologne, CIO Cologne, University of Cologne, Cologne, Germany.
  • Heger JM; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
  • Fuchs M; Department IV of Internal Medicine, University Hospital Aachen, University of Aachen, Aachen, Germany.
  • Engert A; Institute for Medical Statistics, Informatics and Epidemiology (IMSIE), University Hospital of Cologne, University of Cologne, Cologne, Germany.
  • Borchmann P; Department of Hematology and Stem Cell Transplantation and Cancer Center Cologne Essen - Partner Site Essen, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • von Tresckow B; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
Br J Haematol ; 196(3): 606-616, 2022 02.
Article en En | MEDLINE | ID: mdl-34775591
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Enfermedad de Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2022 Tipo del documento: Article País de afiliación: Alemania